Czech blood plasma saga leads to treaty claim

The Czech Republic is facing a billion-dollar investment treaty claim arising from a two-decade dispute with a blood plasma supplier whose efforts to enforce a US$650 million award against the state have been repeatedly thwarted.

Unlock unlimited access to all Global Arbitration Review content